Skip to main content
Erschienen in: World Journal of Urology 10/2016

22.02.2016 | Original Article

Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy

verfasst von: Raphaele Renard Penna, Geraldine Cancel-Tassin, Eva Comperat, Pierre Mozer, Priscilla Léon, Justine Varinot, Morgan Roupret, Marc-Olivier Bitker, Olivier Lucidarme, Olivier Cussenot

Erschienen in: World Journal of Urology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the use of multiparametric MRI (mp MRI) parameters in order to predict prostate cancer aggressiveness as defined by pathological Gleason score or molecular markers in a cohort of patients defined with a Gleason score of 6 at biopsy.

Methods

Sixty-seven men treated by radical prostatectomy (RP) for a low grade (Gleason 6) on biopsy and mp MRI before biopsy were selected. The cycle cell proliferation (CCP) score assessed by the Prolaris test and Ki-67/PTEN expression assessed by immunohistochemistry were quantified on the RP specimens.

Results

49.25 % of the cancers were undergraded on biopsy compared to the RP specimens. Apparent diffusion coefficient (ADC) < 0.80 × 10−3 mm2/s (P value 0.003), Likert score >4 (P value 0.003) and PSA density >0.15 ng/ml/cc (P value 0.035) were significantly associated with a higher RP Gleason score. Regarding molecular markers of aggressiveness, ADC < 0.80 × 10−3 mm2/s and Likert score >4 were also significantly associated with a positive staining for Ki-67 (P value 0.039 and 0.01, respectively). No association was found between any analyzed MRI or clinical parameter and the CCP score.

Conclusion

Decreasing ADC value is a stronger indicator of aggressive prostate cancer as defined by molecular markers or postsurgical histology than biopsy characteristics.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M, Dikshit R et al (2012) GLOBOCAN v1.0, cancer incidence and mortality worldwide: IARC cancer base no. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed on 11/01/2016 Ferlay J, Soerjomataram I, Ervik M, Dikshit R et al (2012) GLOBOCAN v1.0, cancer incidence and mortality worldwide: IARC cancer base no. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://​globocan.​iarc.​fr. Accessed on 11/01/2016
2.
Zurück zum Zitat Partin AW, Kattan MW, Subong EN et al (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277:1445–1451CrossRefPubMed Partin AW, Kattan MW, Subong EN et al (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277:1445–1451CrossRefPubMed
3.
Zurück zum Zitat Sved PD, Gomez P, Manoharan M, Kim SS, Soloway MS (2004) Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer. J Urol 172:98–102CrossRefPubMed Sved PD, Gomez P, Manoharan M, Kim SS, Soloway MS (2004) Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer. J Urol 172:98–102CrossRefPubMed
7.
Zurück zum Zitat Hambrock T, Somford DM, Huisman HJ et al (2011) Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 259:453–461. doi:10.1148/radiol.11091409 CrossRefPubMed Hambrock T, Somford DM, Huisman HJ et al (2011) Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 259:453–461. doi:10.​1148/​radiol.​11091409 CrossRefPubMed
8.
Zurück zum Zitat Tamada T, Sone T, Jo Y et al (2008) Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 28:720–726. doi:10.1002/jmri.21503 CrossRefPubMed Tamada T, Sone T, Jo Y et al (2008) Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 28:720–726. doi:10.​1002/​jmri.​21503 CrossRefPubMed
9.
Zurück zum Zitat Itou Y, Nakanishi K, Narumi Y, Nishizawa Y, Tsukuma H (2011) Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: Can ADC values contribute to assess the aggressiveness of prostate cancer? J Magn Reson Imaging 33:167–172. doi:10.1002/jmri.22317 CrossRefPubMed Itou Y, Nakanishi K, Narumi Y, Nishizawa Y, Tsukuma H (2011) Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: Can ADC values contribute to assess the aggressiveness of prostate cancer? J Magn Reson Imaging 33:167–172. doi:10.​1002/​jmri.​22317 CrossRefPubMed
10.
Zurück zum Zitat Verma S, Rajesh A, Morales H et al (2011) Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol 196:374–381. doi:10.2214/AJR.10.4441 CrossRefPubMed Verma S, Rajesh A, Morales H et al (2011) Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol 196:374–381. doi:10.​2214/​AJR.​10.​4441 CrossRefPubMed
11.
Zurück zum Zitat Renard-Penna R, Cancel-Tassin G, Comperat E et al (2015) Multiparametric magnetic resonance imaging predicts postoperative pathology but misses aggressive prostate cancers as assessed by cell cycle progression score. J Urol 194:1617–1623. doi:10.1016/j.juro.2015.06.107 CrossRefPubMed Renard-Penna R, Cancel-Tassin G, Comperat E et al (2015) Multiparametric magnetic resonance imaging predicts postoperative pathology but misses aggressive prostate cancers as assessed by cell cycle progression score. J Urol 194:1617–1623. doi:10.​1016/​j.​juro.​2015.​06.​107 CrossRefPubMed
12.
Zurück zum Zitat Puech P, Rouviere O, Renard-Penna R et al (2013) Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US–MR fusion guidance versus systematic biopsy-prospective multicenter study. Radiology 268:461–469. doi:10.1148/radiol.13121501 CrossRefPubMed Puech P, Rouviere O, Renard-Penna R et al (2013) Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US–MR fusion guidance versus systematic biopsy-prospective multicenter study. Radiology 268:461–469. doi:10.​1148/​radiol.​13121501 CrossRefPubMed
13.
Zurück zum Zitat Renard-Penna R, Roupret M, Comperat E et al (2013) Accuracy of high resolution (1.5 tesla) pelvic phased array magnetic resonance imaging (MRI) in staging prostate cancer in candidates for radical prostatectomy: results from a prospective study. Urol Oncol 31:448–454. doi:10.1016/j.urolonc.2011.02.017 CrossRefPubMed Renard-Penna R, Roupret M, Comperat E et al (2013) Accuracy of high resolution (1.5 tesla) pelvic phased array magnetic resonance imaging (MRI) in staging prostate cancer in candidates for radical prostatectomy: results from a prospective study. Urol Oncol 31:448–454. doi:10.​1016/​j.​urolonc.​2011.​02.​017 CrossRefPubMed
17.
Zurück zum Zitat Partin AW, Kattan MW, Subong EN et al (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277:1445–1451CrossRefPubMed Partin AW, Kattan MW, Subong EN et al (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277:1445–1451CrossRefPubMed
19.
Zurück zum Zitat Greene KL, Cowan JE, Cooperberg MR et al (2005) Who is the average patient presenting with prostate cancer? Urology 66:76–82CrossRefPubMed Greene KL, Cowan JE, Cooperberg MR et al (2005) Who is the average patient presenting with prostate cancer? Urology 66:76–82CrossRefPubMed
21.
Zurück zum Zitat Itatani R, Namimoto T, Kajihara H et al (2014) Triage of low-risk prostate cancer patients with PSA levels 10 ng/ml or less: comparison of apparent diffusion coefficient value and transrectal ultrasound-guided target biopsy. AJR Am J Roentgenol 202:1051–1057. doi:10.2214/AJR.13.11602 CrossRefPubMed Itatani R, Namimoto T, Kajihara H et al (2014) Triage of low-risk prostate cancer patients with PSA levels 10 ng/ml or less: comparison of apparent diffusion coefficient value and transrectal ultrasound-guided target biopsy. AJR Am J Roentgenol 202:1051–1057. doi:10.​2214/​AJR.​13.​11602 CrossRefPubMed
22.
Zurück zum Zitat De Cobelli F, Ravelli S, Esposito A et al (2015) Apparent diffusion coefficient value and ratio as noninvasive potential biomarkers to predict prostate cancer grading: comparison with prostate biopsy and radical prostatectomy specimen. AJR Am J Roentgenol 204:550–557. doi:10.2214/AJR.14.13146 CrossRefPubMed De Cobelli F, Ravelli S, Esposito A et al (2015) Apparent diffusion coefficient value and ratio as noninvasive potential biomarkers to predict prostate cancer grading: comparison with prostate biopsy and radical prostatectomy specimen. AJR Am J Roentgenol 204:550–557. doi:10.​2214/​AJR.​14.​13146 CrossRefPubMed
24.
Zurück zum Zitat Bittencourt LK, Barentsz JO, de Miranda LC, Gasparetto EL (2012) Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason Grades than TRUS-guided biopsies in peripheral zone tumours. Eur Radiol 22:468–475. doi:10.1007/s00330-011-2269-1 CrossRefPubMed Bittencourt LK, Barentsz JO, de Miranda LC, Gasparetto EL (2012) Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason Grades than TRUS-guided biopsies in peripheral zone tumours. Eur Radiol 22:468–475. doi:10.​1007/​s00330-011-2269-1 CrossRefPubMed
26.
Zurück zum Zitat Renard-Penna R, Mozer P, Cornud F et al (2015) Prostate imaging reporting and data system and Likert scoring system: multiparametric MR imaging validation study to screen patients for initial biopsy. Radiology 275:458–468. doi:10.1148/radiol.14140184 CrossRefPubMed Renard-Penna R, Mozer P, Cornud F et al (2015) Prostate imaging reporting and data system and Likert scoring system: multiparametric MR imaging validation study to screen patients for initial biopsy. Radiology 275:458–468. doi:10.​1148/​radiol.​14140184 CrossRefPubMed
28.
Zurück zum Zitat Benson MC, Whang IS, Pantuck A et al (1992) Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147:815–816PubMed Benson MC, Whang IS, Pantuck A et al (1992) Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147:815–816PubMed
29.
Zurück zum Zitat Revelos K, Petraki C, Gregorakis A et al (2005) p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. In Vivo 19:911–920PubMed Revelos K, Petraki C, Gregorakis A et al (2005) p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. In Vivo 19:911–920PubMed
30.
Metadaten
Titel
Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy
verfasst von
Raphaele Renard Penna
Geraldine Cancel-Tassin
Eva Comperat
Pierre Mozer
Priscilla Léon
Justine Varinot
Morgan Roupret
Marc-Olivier Bitker
Olivier Lucidarme
Olivier Cussenot
Publikationsdatum
22.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 10/2016
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-016-1789-3

Weitere Artikel der Ausgabe 10/2016

World Journal of Urology 10/2016 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.